Joseph Pantginis
Stock Analyst at HC Wainwright & Co.
(1.90)
# 3,064
Out of 4,761 analysts
746
Total ratings
30.81%
Success rate
-7.22%
Average return
Main Sectors:
Stocks Rated by Joseph Pantginis
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| FGEN FibroGen | Reiterates: Buy | $10 | $0.71 | +1,316.63% | 1 | Feb 20, 2025 | |
| KRYS Krystal Biotech | Reiterates: Buy | $221 | $187.86 | +17.64% | 26 | Feb 19, 2025 | |
| PTN Palatin Technologies | Maintains: Buy | $17 → $7 | $1.00 | +600.00% | 29 | Feb 13, 2025 | |
| ESPR Esperion Therapeutics | Reiterates: Buy | $16 | $1.82 | +779.12% | 25 | Feb 11, 2025 | |
| KURA Kura Oncology | Maintains: Buy | $37 → $40 | $8.25 | +384.85% | 24 | Feb 6, 2025 | |
| VKTX Viking Therapeutics | Reiterates: Buy | $102 | $34.07 | +199.38% | 28 | Feb 6, 2025 | |
| NEUP Neuphoria Therapeutics | Maintains: Buy | $8 → $21 | $4.88 | +330.33% | 1 | Feb 4, 2025 | |
| XOMA XOMA Royalty | Maintains: Buy | $123 → $104 | $23.52 | +342.18% | 21 | Feb 3, 2025 | |
| LCTX Lineage Cell Therapeutics | Reiterates: Buy | $9 | $0.68 | +1,231.36% | 9 | Jan 31, 2025 | |
| LXRX Lexicon Pharmaceuticals | Reiterates: Buy | $4 | $0.71 | +463.38% | 18 | Jan 29, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $57 | $20.09 | +183.72% | 25 | Jan 23, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $16 | $6.81 | +134.95% | 17 | Jan 23, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $120 | $50.26 | +138.76% | 44 | Jan 22, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $40 | $3.46 | +1,056.07% | 25 | Jan 16, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $20 | $2.62 | +663.36% | 14 | Jan 15, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $18 | $1.11 | +1,521.62% | 13 | Jan 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $5.75 | $2.74 | +109.85% | 19 | Jan 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $2 | $0.96 | +108.55% | 12 | Jan 10, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $10 | $2.92 | +242.47% | 16 | Jan 10, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $2 | $0.16 | +1,133.81% | 15 | Jan 10, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $77 | $15.00 | +413.33% | 18 | Jan 2, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $80 | $22.46 | +256.19% | 29 | Dec 20, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $7 | $2.11 | +232.54% | 14 | Dec 19, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $21 | $1.34 | +1,467.16% | 26 | Dec 18, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $25 | $2.31 | +982.25% | 16 | Dec 18, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $37 | $8.86 | +317.61% | 14 | Dec 17, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $20 | $3.13 | +538.98% | 17 | Dec 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $15 | $2.55 | +488.51% | 16 | Dec 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | n/a | $120.67 | - | 20 | Dec 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $35 | $4.32 | +710.19% | 6 | Dec 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $10 | $0.42 | +2,309.64% | 1 | Dec 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | n/a | $4.03 | - | 7 | Dec 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $840 → $360 | $3.59 | +9,927.86% | 11 | Nov 25, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $24 → $26 | $1.62 | +1,504.94% | 3 | Nov 18, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $4 | $1.17 | +241.88% | 22 | Nov 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | n/a | $1.37 | - | 17 | Nov 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $11 | $3.65 | +201.37% | 6 | Nov 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $31 | $4.43 | +599.77% | 26 | Nov 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $16 | $2.35 | +580.85% | 9 | Nov 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $47 | $0.86 | +5,362.58% | 17 | Nov 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $3 → $32 | $19.89 | +60.88% | 5 | Nov 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $9 | $2.23 | +303.59% | 3 | Nov 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $32 | $5.78 | +453.63% | 26 | Nov 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $25 | $3.96 | +531.31% | 4 | Oct 2, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $21 | $7.59 | +176.68% | 7 | Aug 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $100 | $2.95 | +3,289.83% | 7 | May 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $1.79 | - | 6 | Dec 1, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $36 → $32 | $1.72 | +1,760.47% | 4 | Feb 25, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $30 | $2.70 | +1,011.11% | 2 | Nov 3, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $2.43 | - | 2 | Jan 31, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Buy | $18 → $33 | $30.88 | +6.87% | 2 | Nov 14, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $60 → $78 | $5.68 | +1,273.24% | 1 | Mar 24, 2017 |
FibroGen
Feb 20, 2025
Reiterates: Buy
Price Target: $10
Current: $0.71
Upside: +1,316.63%
Krystal Biotech
Feb 19, 2025
Reiterates: Buy
Price Target: $221
Current: $187.86
Upside: +17.64%
Palatin Technologies
Feb 13, 2025
Maintains: Buy
Price Target: $17 → $7
Current: $1.00
Upside: +600.00%
Esperion Therapeutics
Feb 11, 2025
Reiterates: Buy
Price Target: $16
Current: $1.82
Upside: +779.12%
Kura Oncology
Feb 6, 2025
Maintains: Buy
Price Target: $37 → $40
Current: $8.25
Upside: +384.85%
Viking Therapeutics
Feb 6, 2025
Reiterates: Buy
Price Target: $102
Current: $34.07
Upside: +199.38%
Neuphoria Therapeutics
Feb 4, 2025
Maintains: Buy
Price Target: $8 → $21
Current: $4.88
Upside: +330.33%
XOMA Royalty
Feb 3, 2025
Maintains: Buy
Price Target: $123 → $104
Current: $23.52
Upside: +342.18%
Lineage Cell Therapeutics
Jan 31, 2025
Reiterates: Buy
Price Target: $9
Current: $0.68
Upside: +1,231.36%
Lexicon Pharmaceuticals
Jan 29, 2025
Reiterates: Buy
Price Target: $4
Current: $0.71
Upside: +463.38%
Jan 23, 2025
Reiterates: Buy
Price Target: $57
Current: $20.09
Upside: +183.72%
Jan 23, 2025
Reiterates: Buy
Price Target: $16
Current: $6.81
Upside: +134.95%
Jan 22, 2025
Reiterates: Buy
Price Target: $120
Current: $50.26
Upside: +138.76%
Jan 16, 2025
Reiterates: Buy
Price Target: $40
Current: $3.46
Upside: +1,056.07%
Jan 15, 2025
Reiterates: Buy
Price Target: $20
Current: $2.62
Upside: +663.36%
Jan 14, 2025
Reiterates: Buy
Price Target: $18
Current: $1.11
Upside: +1,521.62%
Jan 14, 2025
Reiterates: Buy
Price Target: $5.75
Current: $2.74
Upside: +109.85%
Jan 10, 2025
Reiterates: Buy
Price Target: $2
Current: $0.96
Upside: +108.55%
Jan 10, 2025
Reiterates: Buy
Price Target: $10
Current: $2.92
Upside: +242.47%
Jan 10, 2025
Reiterates: Buy
Price Target: $2
Current: $0.16
Upside: +1,133.81%
Jan 2, 2025
Reiterates: Buy
Price Target: $77
Current: $15.00
Upside: +413.33%
Dec 20, 2024
Reiterates: Buy
Price Target: $80
Current: $22.46
Upside: +256.19%
Dec 19, 2024
Reiterates: Buy
Price Target: $7
Current: $2.11
Upside: +232.54%
Dec 18, 2024
Reiterates: Buy
Price Target: $21
Current: $1.34
Upside: +1,467.16%
Dec 18, 2024
Reiterates: Buy
Price Target: $25
Current: $2.31
Upside: +982.25%
Dec 17, 2024
Reiterates: Buy
Price Target: $37
Current: $8.86
Upside: +317.61%
Dec 16, 2024
Reiterates: Buy
Price Target: $20
Current: $3.13
Upside: +538.98%
Dec 11, 2024
Reiterates: Buy
Price Target: $15
Current: $2.55
Upside: +488.51%
Dec 11, 2024
Reiterates: Buy
Price Target: n/a
Current: $120.67
Upside: -
Dec 10, 2024
Reiterates: Buy
Price Target: $35
Current: $4.32
Upside: +710.19%
Dec 9, 2024
Initiates: Buy
Price Target: $10
Current: $0.42
Upside: +2,309.64%
Dec 5, 2024
Reiterates: Neutral
Price Target: n/a
Current: $4.03
Upside: -
Nov 25, 2024
Maintains: Buy
Price Target: $840 → $360
Current: $3.59
Upside: +9,927.86%
Nov 18, 2024
Maintains: Buy
Price Target: $24 → $26
Current: $1.62
Upside: +1,504.94%
Nov 15, 2024
Reiterates: Buy
Price Target: $4
Current: $1.17
Upside: +241.88%
Nov 15, 2024
Reiterates: Neutral
Price Target: n/a
Current: $1.37
Upside: -
Nov 14, 2024
Reiterates: Buy
Price Target: $11
Current: $3.65
Upside: +201.37%
Nov 14, 2024
Reiterates: Buy
Price Target: $31
Current: $4.43
Upside: +599.77%
Nov 14, 2024
Reiterates: Buy
Price Target: $16
Current: $2.35
Upside: +580.85%
Nov 13, 2024
Reiterates: Buy
Price Target: $47
Current: $0.86
Upside: +5,362.58%
Nov 11, 2024
Maintains: Buy
Price Target: $3 → $32
Current: $19.89
Upside: +60.88%
Nov 11, 2024
Reiterates: Buy
Price Target: $9
Current: $2.23
Upside: +303.59%
Nov 6, 2024
Reiterates: Buy
Price Target: $32
Current: $5.78
Upside: +453.63%
Oct 2, 2024
Reiterates: Buy
Price Target: $25
Current: $3.96
Upside: +531.31%
Aug 6, 2024
Reiterates: Buy
Price Target: $21
Current: $7.59
Upside: +176.68%
May 16, 2024
Reiterates: Buy
Price Target: $100
Current: $2.95
Upside: +3,289.83%
Dec 1, 2021
Downgrades: Neutral
Price Target: n/a
Current: $1.79
Upside: -
Feb 25, 2021
Maintains: Buy
Price Target: $36 → $32
Current: $1.72
Upside: +1,760.47%
Nov 3, 2020
Upgrades: Buy
Price Target: $30
Current: $2.70
Upside: +1,011.11%
Jan 31, 2018
Downgrades: Neutral
Price Target: n/a
Current: $2.43
Upside: -
Nov 14, 2017
Assumes: Buy
Price Target: $18 → $33
Current: $30.88
Upside: +6.87%
Mar 24, 2017
Reiterates: Buy
Price Target: $60 → $78
Current: $5.68
Upside: +1,273.24%